Continuous combined hormone replacement therapy and endometrial hyperplasia

doi:10.1136/bmj.325.7358.231

BMJ 2002;325:231-232 ( 3 August )

Editorials

Continuous combined hormone replacement therapy and endometrial hyperplasia

Risk of developing cancer is very low

Papers p 239

The first 150 words of the full text of this article appear below.

The use of continuous combined hormone replacement therapy, consisting of an oestrogen and a progestogen taken daily by postmenopausalwomen, is increasing. Its possible benefits are the preventionof endometrial hyperplasia and reduction in the occurrence ofendometrial bleeding with time. Daily exposure to oestrogen andprogestin without a break may be more important than using oestrogenintermittently in prevention of disease. A major concern is theoccurrence of endometrial cancer in women using cyclic or sequentialhormone replacement with the progestin being given for eitherless than 10 days each month, 10-16 days each month, or everythree months for 14 days. ¹ ² The case-control studies indicatea significant increased risk in endometrial cancer with a reductionin the number of days of exposure to progestin. The use of continuouscombined hormone replacement therapy not only does not increasethe incidence of endometrial cancer but could even be protectivecompared with non-use of . . . [Full text of this article]

CiteULike

Complore

Connotea

Del.icio.us Add to Digg

Digg

StumbleUpon Add to Technorati

Technorati What's this?

Relevant Article

Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study: Michael Wells, David W Sturdee, David H Barlow, Lian G Ulrich, Karen O'Brien, Michael J Campbell, Martin P Vessey, and Anthony J Bragg
BMJ 2002 325: 239. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

Hampton, N.R.E., Rees, M.C.P., Lowe, D.G., Rauramo, I., Barlow, D., Guillebaud, J. (2005). Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 20: 2653-2660 [Abstract] [Full text]